Patients taking denosumab to treat osteoporosis found a higher mean increase in spine bone mineral density, while patients treated with zoledronic acid had an increase in flu-like symptoms while taking the drug, according to researchers from Loyola University and the University of Notre Dame.
“Both groups of patients were satisfied with their treatment despite the discrepancies in the drugs,” Kellen Sheedy, a student at Stritch School of Medicine, stated in a press release.
Sheedy, Pauline Camacho, MD, and colleagues retrospectively analyzed 107 patients who were taking either denosumab or zoledronic acid for the treatment of osteoporosis, according to the abstract. The researchers reported no significant differences in femur T-score and bone mineral density, or spine T-score at 1 year. They also noted no significant differences in bone-specific alkaline phosphatase, back pain, muscle pain or patient satisfaction.Full Story »